YOLFTbeta
16

CORESTEM Inc

166480 · KQ · Healthcare / Biotechnology

1,390.00KRW-25.00 (-1.77%)

Price History

Full chart

Market Stats

Previous Close1,415.00
Open1,451.00
Day Range1,312.00 – 1,470.00
52-Week Range1,014.00 – 5,090.00
Volume160.96K
Market Cap109.90B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.59
50-Day Avg2,071.44
200-Day Avg2,546.00

About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Kyung-Suk Kim
  • Employees36
  • Headquarters24 Pangyo-ro 255beon-gil, Seongnam-si, South Korea, 13486, Korea
  • Websitehttps://www.corestem.com

Leadership

  • Ms. Kyung-Suk KimChief Executive Officer · b. 1965

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue12.99B18.57B17.95B18.09B22.32B24.28B26.36B30.24B46.29B33.66B28.76B20.16B
Growth (%)-+42.99%-3.33%+0.79%+23.34%+8.82%+8.54%+14.73%+53.09%-27.30%-14.54%-29.91%
Cost of Revenue9.43B12.50B12.74B14.63B18.06B19.35B21.41B22.25B30.66B30.16B29.88B24.23B
Gross Profit3.56B6.07B5.21B3.47B4.25B4.94B4.95B7.99B15.63B3.49B-1.12B-4.07B
Gross Margin27.38%32.70%29.04%19.16%19.06%20.34%18.78%26.41%33.76%10.38%-3.89%-20.19%
Operating Expense5.36B4.70B6.84B8.54B8.27B10.03B11.96B18.54B23.26B25.06B19.21B17.15B
Operating Income-1.80B1.37B-1.62B-5.07B-4.02B-5.09B-7.01B-10.55B-7.63B-21.57B-20.33B-21.22B
Operating Margin-13.89%7.36%-9.04%-28.02%-18.02%-20.95%-26.60%-34.89%-16.48%-64.09%-70.68%-105.28%
EBITDA--------13.46B-9.03B-22.04B-20.95B
EBITDA Margin--------29.08%-26.83%-76.61%-103.92%
Net Income-6.80B-511.72M-1.66B-4.01B-3.40B-5.17B-23.19B-7.00B-2.66B-17.67B-26.25B-26.83B
Net Income Margin-52.37%-2.76%-9.27%-22.14%-15.22%-21.28%-87.97%-23.14%-5.74%-52.50%-91.27%-133.11%
R&D977.80M667.71M1.49B3.16B2.93B-5.88B12.13B11.38B12.76B12.68B7.19B
R&D as % of Total Revenue7.53%3.60%8.29%17.46%13.14%-22.32%40.11%24.59%37.92%44.09%35.65%
Interest Expense0000002.29B5.07B5.46B3.76B4.49B1.69B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%8.70%16.77%11.80%11.17%15.60%8.36%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets35.99B74.95B85.69B90.67B89.26B85.65B142.87B136.41B78.61B78.59B117.46B112.37B
Total Liabilities17.02B11.92B18.96B25.07B27.03B27.95B101.59B99.22B37.15B58.99B68.86B57.20B
Total Equity11.53B63.04B66.73B65.60B62.24B57.70B41.29B37.19B41.46B19.60B48.59B55.17B
Cash2.27B12.88B160200290-28033.87B5.91B2.10B4.74M1.27B2.34B
Total Debt---1.21B--4.40B-----
Net Debt-------20.61B15.63B29.60B44.62B35.88B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.45B-1.02B3.50B-6.29B-1.13B-538.08M4.47B-7.65B-8.42B-15.70B-21.12B-13.87B
Investing Cash Flow-9.14B-19.38B-24.74B85.13M2.15B-277.35M-34.78B-24.03B55.46B-9.30B-24.65B-
Financing Cash Flow5.93B36.45B11.21B1.33B30.00M-620.39M61.16B3.72B-50.85B25.14B44.74B-
Capital Expenditure3.84B1.98B5.26B10.67B3.06B3.82B5.00B15.04B9.91B9.27B23.04B2.06B
Free Cash Flow-------552.94M-23.88B-18.33B-24.97B-44.16B-15.92B
FCF to OCF-------12.38%312.33%217.75%159.07%209.09%114.82%

Earnings

Report DateAug 14, 2015Nov 15, 2015Feb 24, 2016May 13, 2016Aug 26, 2016Nov 15, 2016Mar 2, 2017May 9, 2017Aug 10, 2017Nov 13, 2017Mar 2, 2018May 14, 2018Aug 14, 2018Nov 14, 2018Mar 5, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 17, 2020May 14, 2020Aug 14, 2020Nov 16, 2020Feb 25, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------
EPS Actual17.075.93-17.58-49.00-24.1139.73-72.48-57.36-38.52-38.59-120.44-7.32-81.18-17.99-108.95-36.58-19.77-65.23-207.25-66.41-68.00-183.00-1157.93432.20-942.19-142.46288.32-112.3318.25-139.64-368.16-104.17-93.03-177.66-305.14-421.01-505.40-161.07125.29-77.57-240.02-257.35-270.51-144.31-76.47
Surprise---------------------------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market----------------------

Key Statistics & Ratios

Market Cap109.90B
Enterprise Value135.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.02
Price / Book2.30
Revenue (TTM)18.29B
Gross Profit (TTM)-4.90B
EBITDA-17.01B
Profit Margin-152.02%
Operating Margin-79.33%
Return on Equity-61.95%
Return on Assets-11.97%
Shares Outstanding48.10M
Shares Float42.56M
Beta1.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 17, 20252827:2297